In a significant step toward improving access to influenza treatment, the U.S. Food and Drug Administration (FDA) has approved the first generic version of baloxavir marboxil tablets, a single-dose antiviral medicine used for the treatment and prevention of influenza. The approval comes just before the start of the 2026-27 flu season and is expected to provide patients with a more affordable treatment option.
The newly approved generic product, developed by Norwich Pharmaceuticals, is the generic equivalent of Xofluza (baloxavir marboxil), a medicine originally approved by the FDA in 2018. Xofluza gained attention as the first single-dose oral treatment for influenza, offering a convenient alternative to traditional antiviral therapies that require multiple doses over several days.
Baloxavir marboxil is indicated for the treatment of acute uncomplicated influenza in patients aged 5 years and older who have experienced symptoms for no more than 48 hours. The medicine is approved for use in otherwise healthy individuals as well as those considered at high risk for developing flu-related complications. In addition to treatment, it can also be used to help prevent influenza following exposure to an infected person.
Unlike commonly used antiviral medications that must be taken twice daily for five days, baloxavir marboxil is administered as a single oral dose. The drug works by inhibiting viral replication, helping to stop the influenza virus from multiplying inside the body. This simplified dosing schedule may improve patient adherence and enable faster initiation of treatment during flu outbreaks.
Health experts emphasize that antiviral medicines are most effective when started within the first 48 hours after flu symptoms appear. Early treatment can reduce the severity and duration of illness and may help lower the risk of complications, particularly among vulnerable populations such as older adults and individuals with chronic medical conditions.
According to the FDA, the most commonly reported side effects associated with baloxavir marboxil include diarrhea, bronchitis, nausea, sinusitis, and headache. Healthcare professionals are advised to review prescribing information before use and consider patient-specific factors when selecting antiviral therapy.
The approval reflects ongoing efforts to expand the availability of generic medicines in the United States. By introducing competition into the market, generic versions can help reduce treatment costs while maintaining the same standards of quality, safety, and effectiveness as the branded product.
With influenza continuing to cause millions of illnesses worldwide each year, the availability of the first generic single-dose flu treatment marks an important development in public health and could improve access to timely antiviral therapy for patients during upcoming flu seasons.
